Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study

G. Corazzelli, F. Russo, G. Capobianco, G. Marcacci, P. Della Cioppa, A. Pinto

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study'. Together they form a unique fingerprint.

Medicine & Life Sciences